Pfizer submits data to FDA for authorization for COVID booster shots for general population

Pfizer and BioNTech said Monday they have submitted early stage clinical trial data to the Food and Drug Administration as part of their U.S. application seeking authorization of a Covid vaccine booster for everyone 16 and older — not just people with weak immune systems.

Tuesday, August 17, 2021 - 12:48pm